On September 30, 2013, the Company entered into an unsecured short-term Convertible Promissory Note in the principal amount of $1,956,000 bearing interest at 3.00% as partial consideration for the Technology Access Fees associated with the Probiotic ECC (discussed below) entered into with Intrexon Corporation. The Convertible Promissory Note is payable, at the Company’s option, in cash or shares of the Company’s common stock. Principal and accrued interest are due on December 31, 2013.